NASDAQ$XXII

22nd Century Group Inc. · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Net sales increased significantly due to GVB Biopharma acquisition and increased contract manufacturing volumes.

22nd Century Group reported a significant increase in net sales for Q3 2022, driven by the acquisition of GVB Biopharma and increased contract manufacturing volumes. The company is expanding its VLN® product launch and focusing on key geographies and markets. The company's hemp/cannabis revenue is also growing, with plans to increase gross margin through the startup of a new crude extraction plant and additional certifications.

  • Net sales increased by 148% to $19.4 million compared to Q3 2021.
  • VLN® product launch expanded to five states with plans to reach 18 states within twelve months.
  • GVB Biopharma acquisition contributed to hemp/cannabis revenue, positioning the company as the largest merchant market supplier of CBD in North America.
  • Company is focused on increasing gross margins and driving market share across its business units.

Headline financials

Total Revenue

$19.4M

Previous: $7.81M+148.2%
EPS (adj)

-$14.40

Previous: -$14.40+0.0%
Capital Expenditures

-$2.5M

Previous: -$470K-432.1%
Free Cash Flow

-$15.6M

Previous: -$9.91M-57.4%
Net Income

-$13.1M

Previous: -$9.44M-38.8%
Operating Income

-$15.3M

Previous: -$7.57M-101.7%
Gross Profit

-$18.8M

Previous: -$7.36M-154.9%
Cash & Equivalents

$2.36M

Previous: $1.63M+45.1%
Total Assets

$142M

Previous: $86.5M+64.5%
Stock-Based Comp

$2.25M

Previous: $1.12M+100.8%

Revenue & EPS history

22nd Century Group · Revenue · Quarterly

$19.4M

Q3 2022+148.2%vs Q3 2021
Beat estimate in 3 of 10 quarters(30%)
ActualEstimate

Forward guidance

22nd Century Group anticipates a decrease in cash requirements, reflecting higher sales volume of higher margin contract manufacturing operations (CMO) cigarettes and VLN® products through fiscal 2023, and continued organic growth of GVB’s operations, providing adequate liquidity from the current balance sheet to complete its planned strategic initiatives.

Tailwinds

  • Higher sales volume of higher margin contract manufacturing operations (CMO) cigarettes
  • Higher sales volume of VLN® products through fiscal 2023
  • Continued organic growth of GVB’s operations
  • Adequate liquidity from the current balance sheet
  • Planned strategic initiatives

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-2.9%

Avg return

Earnings day

-3.9%

Avg return

5 days after

-7.7%

Avg return

30 days after

32%

19 / 59 earnings

Positive

+37.4%

Q4 2020

Best reaction

-25.8%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.2%-13.2%
Q1 2026-16.6%-33.2%-44.0%
Q3 2025-17.0%-20.0%-32.3%
Q1 2025+1.9%-18.7%-59.3%
Q4 2024-2.6%-12.6%-59.2%
Q3 2024-3.0%-10.7%-28.2%
Q2 2024-14.9%-21.9%-62.8%
Q1 2024-1.9%-9.7%-47.9%
Q4 2023-8.7%-7.7%-18.1%
Q3 2023-15.2%-19.0%-52.5%
Q2 2023-25.8%-23.3%-51.6%
Q1 2023-5.0%-13.8%-16.1%
Q4 2022-0.7%-4.9%-17.9%
Q3 2022-21.0%-13.8%-26.1%
Q2 2022-10.7%-11.2%-32.7%
Q1 2022-8.3%-20.3%-3.1%
Q4 2021-2.1%-9.8%-0.9%
Q3 2021-0.7%+1.7%-22.1%
Q2 2021+18.1%+26.4%+12.4%
Q1 2021+8.4%+10.7%+14.9%
Q4 2020+37.4%+27.0%+62.6%
Q3 2020+13.2%+12.5%+129.0%
Q2 2020-2.1%-4.6%-19.3%
Q1 2020-3.6%-9.9%-7.7%
Q4 2019-5.8%+2.2%-7.7%
Q3 2019-3.6%-10.2%-40.8%
Q2 2019+3.1%+18.9%+31.4%
Q1 2019-11.4%-18.6%-18.1%
Q4 2018+1.6%+7.0%+1.1%
Q3 2018+3.1%+0.8%+9.8%
Q2 2018-1.6%+2.8%+2.4%
Q1 2018+6.8%+23.2%+7.7%
Q4 2017+11.3%+5.8%-10.1%
Q3 2017+0.0%+5.8%+28.6%
Q2 2017-7.9%-10.5%+4.6%
Q1 2017+6.9%+6.9%+40.5%
Q4 2016+0.5%+3.7%+44.4%
Q3 2016+0.8%-0.8%-21.2%
Q2 2016+2.2%+10.9%+17.4%
Q1 2016+2.6%
Q4 2015-4.8%
Q3 2015-9.3%
Q2 2015-7.0%
Q1 2015+21.5%
Q4 2014-16.5%
Q4 2013-16.5%
Q3 2014-9.2%
Q2 2014-1.4%
Q1 2014-2.9%
Q3 2013+4.2%
Q2 2013-18.5%
Q1 2013+0.0%
Q4 2012-9.1%
Q3 2012-20.0%
Q2 2012-7.1%
Q1 2012+1.5%
Q4 2011+1.5%
Q3 2011+0.0%
Q2 2011+0.0%
Q4 2010
Q3 2010
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro